Key Words: cardiovascular disease ◼ drug-related side effects and adverse reactions ◼ Hydroxymethylglutaryl-CoA reductase inhibitors ◼ nocebo effect DATA REPORT W hen compared against placebo in randomized trials, statins are extremely well tolerated, causing muscle-related side effects in 1% or fewer of treated patients.
METHODS AND RESULTS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results. The PALM Registry enrolled 7938 patients from 140 primary care, cardiology, and endocrinology practices in the United States (May 27, 2015 to November 12, 2015) and has been described in detail. 5 Trained study coordinators identified eligible patients (patients on a statin, at risk for cardiovascular disease [CVD] , or with prevalent CVD, in the Data Supplement) at the time of their visit, who were then sequentially enrolled. Of 9788 eligible patients, n=7937 (81%) consented and enrolled in the study. Patients were then surveyed on statin use, perceived statin-related symptoms and response to symptoms, beliefs about statins and CVD, and sociodemographic characteristics (response rate 95.3%, in the Data Supplement).
Clinical characteristics and medications were abstracted from the medical record by study coordinators. All patients had core laboratory lipid levels (LabCorp, Burlington, NC). Categorical variables were compared with Mantel-Haenszel χ 2 tests and continuous variables using Wilcoxon rank-sum tests. Multivariable logistic regression modeling was used to evaluate factors associated with symptoms using generalized estimating equations to account for clustering within site, with backward model selection at P<0.05 for variable retention. Candidate variables were chosen based on either associations with statin use (eg, demographics, atherosclerotic cardiovascular disease history, education, and insurance) or prior associations with statin intolerance (eg, thyroid disease and body mass index). Continuous variables were modeled using splines to account for nonlinearity. Statistical analyses were performed using SAS version 9.4 (Cary, NC). All participants provided signed informed consent. Each site obtained institutional review board approval for participation.
Frequency and Types of Statin-Associated Symptoms
Among 7563 patients, 5916 (78.2%) reported ever using a statin (5316 current, 600 former). Among former users, the time since the last statin use was <1 month for 13%, 1 month to <1 year for 29%, 1 to 5 years for 33%, and >5 years for 17%. Overall, 2600 reported at least 1 symptom while on statin therapy, including 41.8% of current users and 63.2% of prior users. The most commonly reported symptoms were muscle aches/cramps (29% current, 51% former), fatigue (14% current, 20% former), and weakness (10% current, 20% former). Memory loss was reported by 10% of current and 9% of prior statin users, followed by constipation (9% current, 8% former), nausea (5% current, 8% former), hives/itching (3% current, 5% former), and other (1% current, 2% former). Those with symptoms reported lower beliefs in statin efficacy and safety and were less likely to report completely trusting their doctor (Table) . Symptomatic patients reported increased worry about CVD compared with those without symptoms.
Factors Associated With Symptoms

Statin Intensity and LDL-C Levels in Current Statin Users
Among current statin users, there was no difference in the rate of high-intensity statin use by symptom reporting (30.3% with symptoms versus 28.2% without; P=0.11), but those with symptoms were slightly more likely to be taking nonstatin lipid-lowering therapy (27.4% versus 25.0%; P=0.049). LDL-C (low-density lipoprotein cholesterol) levels were higher among those with symptoms compared with those without (median, 89.0 versus 86.0 mg/dL; P<0.001).
Response to Symptoms
Most patients (50.8% overall) tried at least 1 intervention to stay on statin therapy. Among current statin users, 57.0% of symptomatic patients reported not taking any action to treat the symptom, 24.0% switched statins, 11.3% stopped then rechallenged with the same statin, 12.2% reduced the dose, 8.1% added an additional medication, 5.5% reduced statin frequency, and 2.8% reduced exercise. Among symptomatic former statin users, 25.9% reported no intervention, 33.4% switched statins, 39.1% stopped then rechallenged, 19.1% reduced the dose, 11.1% added an additional medication, 10.9% reduced statin frequency, and 2.6% reduced exercise.
Impact on Medication Persistence
Adverse effects were the leading reason for discontinuing therapy (51.2% of former users discontinued because of side effects). Willingness to retry a statin among those who discontinued because of symptoms was high; 26.8% reported they would not at all be willing to retry a statin, 17.8% were unlikely, 23.1% possibly, 18.2% were very likely, and 11.5% reported they would almost certainly retry a statin.
COMMENT
Despite data from randomized trials supporting the safety of statin therapy and very low rates of excess muscle-related complaints when statins are compared with placebo, very high numbers of adults who take statins continue to report statin-associated symptoms. In our study of adults currently or formerly on statin therapy in routine clinical practice, 41.8% of current and 63.2% of former statin users report at least 1 symptom on statin therapy. This is consistent with prior observational studies, with rates of muscle-related complaints ranging from 10% to 69% in different analyses. 3, 6 Groups most likely to report symptoms included women and those with diabetes mellitus or thyroid disease, consistent with other studies. 6 Patients with coronary artery disease and those with higher levels of education were also more likely to report symptoms. Symptomatic patients felt less sure that statins were efficacious and were less likely to report completely trusting their doctor.
Our study does not establish causation between statin use and symptoms. In clinical trials, statins have not been shown to cause any of the symptoms that participants were asked about except for muscle-related symptoms. Further, the rates of muscle-related symptoms seen in PALM exceed that shown in trials. 4 This suggests that patients are likely misattributing symptoms with a high background incidence to their statin. Furthermore, patients with negative expectations about statin adverse effects may be more likely to experience them (the nocebo effect). 7 Adults who reported symptoms on statins were more likely to worry about CVD, potentially reflecting a higher level of health-related anxiety. Whether real or not, perceived statin-related symptoms often led patients to discontinue therapy. Our data offer hope for improving statin utilization. Many adults with symptoms successfully continued statin therapy, and nearly half of former users were willing to retry a statin. This is consistent with previous studies showing that many who discontinue statin therapy can tolerate rechallenge. 8, 9 Although current guidelines recommend that patients presenting with symptoms be rechallenged to establish causation before switching to an alternate statin, 10 patients who continued on therapy were more likely to report switching to another statin or changing the dose. In contrast, rechallenge was more common among those who ultimately stopped therapy. Optimal strategies to identify true versus perceived statin intolerance while balancing patient preferences remain unclear.
Limitations
First, patients were queried about symptoms rather than side effects while on a statin. The patient survey High-intensity statin defined as atorvastatin ≥40 mg, rosuvastatin ≥20 mg. Statin intensity not assessed in former statin users. Categorical variables presented as median (25th-75th percentile). BMI indicates body mass index; BP, blood pressure; CAD, coronary artery disease; CKD, chronic kidney disease; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; and TIA, transient ischemic attack.
was intentionally designed this to prevent patients from inferring causation between statins and all the symptoms listed, which included symptoms that are not known to be associated with statins. Second, our analysis of the interventions that were tried after symptom onset was based on patient report, which may be subject to recall bias. Third, only current therapy was confirmed by chart review, not prior therapy. Fourth, participants who volunteered for PALM may have been more likely to have stronger opinions about statins than the general population, because of volunteer bias. Finally, though the survey was pilot tested during development, formal reliability and validity testing was not performed.
Conclusions
In community practice, more than half of adults formerly or currently on statins reported symptoms while on statin therapy, which was the leading cause of statin discontinuation. Given the preponderance of evidence about statin safety from randomized trials, much of this is likely because of misattribution of background symptoms to statins. Even among those on statins, those with symptoms had higher LDL-C levels, potentially reflecting lower adherence. Those reporting symptoms also had less belief in statin efficacy and safety and less trust in their doctors. Although many patients did not attempt rechallenge, the majority of adults who discontinued statins because of side effects were willing to be rechallenged. These data underscore the magnitude of perceived statin-associated symptoms in community practice and support the need for more robust intervention strategies to address both real and perceived symptoms of statin therapy.
